Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 13/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.42 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.42 |
| ▸ | RARA | P10276 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 1/20 | 0.42 |
| ▸ | RARG | P13631 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2664787 | 0.89 | GCK (0.71) | GCKCSNK2A2CSNK2A1RARARARB | |
| SCHEMBL2664684 | 0.87 | GCK (0.66) | GCKSMN1; SMN2 | |
| SCHEMBL2664826 | 0.85 | GCK (0.66) | GCKSMN1; SMN2 | |
| SCHEMBL2664775 | 0.85 | GCK (0.68) | GCKSMN1; SMN2 | |
| SCHEMBL15925182 | 0.85 | GCK (0.65) | GCKRARARARBRARG | |
| SCHEMBL2555655 | 0.84 | GCK (0.69) | GCKCSNK2A2CSNK2A1RARARARB | |
| SCHEMBL31456328 | 0.84 | GCK (0.69) | GCKCSNK2A2CSNK2A1RARARARB | |
| SCHEMBL2664677 | 0.84 | GCK (0.66) | GCKRARARARBRARG | |
| SCHEMBL12021204 | 0.83 | GCK (0.63) | GCKRARARARBRARG | |
| SCHEMBL2664083 | 0.83 | GCK (0.60) | GCKSMN1; SMN2RARARARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-20110034432-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATING AGENTS | ASTRAZENECA AB (SE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034432-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATING AGENTS | ASTRAZENECA AB (SE) | 2011-02-10 | — | — | US | disclosed |
| US-7745475-B2 | Such as 3-[(1S)-2-hydroxy-1-methylethoxy]-5-[4-(methylsulfonyl)phenoxy]-N-1,3-thiazol-2-ylbenzamide; glucokinases (Glk) | ASTRAZENECA AB (SE) | 2010-06-29 | — | — | US | disclosed |
| US-7745475-B2 | Such as 3-[(1S)-2-hydroxy-1-methylethoxy]-5-[4-(methylsulfonyl)phenoxy]-N-1,3-thiazol-2-ylbenzamide; glucokinases (Glk) | ASTRAZENECA AB (SE) | 2010-06-29 | — | — | US | disclosed |
| US-20090253676-A1 | Heteroaryl Benzamide Derivatives for Use as GLK Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253676-A1 | Heteroaryl Benzamide Derivatives for Use as GLK Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2009-10-08 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20080207636-A1 | Compounds Effecting Glucokinase | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207636-A1 | Compounds Effecting Glucokinase | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-7390908-B2 | Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes | ASTRAZENECA AB (SE) | 2008-06-24 | — | — | US | disclosed |
| US-7390908-B2 | Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes | ASTRAZENECA AB (SE) | 2008-06-24 | — | — | US | disclosed |
| US-20080015203-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-20080015203-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| US-20070287693-A1 | Benzamide Derivatives That Act Upon The Glucokinase Enzyme | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | US | disclosed |
| US-20070287693-A1 | Benzamide Derivatives That Act Upon The Glucokinase Enzyme | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | US | disclosed |
| EP-1568367-B1 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2007-04-18 | — | — | EP | disclosed |
| WO-2005080360-A1 | COMPOUNDS | ASTRAZENECA AB (SE) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015203-A1 | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes | GRK4, GRK5, GRK2 | GCK 9/4885SMN1; SMN2 2982/4885CSNK2A2 1072/4885 |
| US-20070287693-A1 | Benzamide Derivatives That Act Upon The Glucokinase Enzyme | GCK, GCKR, GRK4 | GCK 1/4885SMN1; SMN2 2938/4885CSNK2A2 760/4885 |
| US-20110034432-A1 | BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINASE ACTIVATING AGENTS | GCK, GCKR, GRK4 | GCK 1/4885SMN1; SMN2 2868/4885CSNK2A2 635/4885 |
| US-20090253676-A1 | Heteroaryl Benzamide Derivatives for Use as GLK Activators in the Treatment of Diabetes | GRK4, GRK5, GRK2 | GCK 9/4885SMN1; SMN2 3067/4885CSNK2A2 1090/4885 |
| US-20080207636-A1 | Compounds Effecting Glucokinase | GCKR, GCK, SLC5A2 | GCK 2/4885SMN1; SMN2 1886/4885CSNK2A2 444/4885 |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | GCKR, GCK, SLC5A2 | GCK 2/4885SMN1; SMN2 1886/4885CSNK2A2 444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.